Gene expression profiling of INA-6 cells expressing mutated EpoR/gp130 chimeras. INA-6 strains expressing the indicated EpoR/gp130 chimeras were deprived of IL-6 for 12 hours before stimulation with Epo for 1 hour. Gene expression was analyzed by using Affymetrix U95A arrays (5 columns at the right). Two independent experimental series were carried out. The values are compared with those obtained for unmanipulatied INA-6 cells after treatment with IL-6 for 1 hour (left column). (A) Expression change values (fold) are shown for the genes significantly responding to a 1-hour IL-6 treatment of INA-6 cells by at least 2-fold. Dark gray background indicates change values significant (described in “Materials and methods”) in both experiments, light gray values significant in only one of the 2 experiments. (B) Values are shown for the genes significantly responding to IL-6 treatment by 1.5- to 2-fold and (C) for the genes changed through EpoR/gp130 but not significantly changed by IL-6 in INA-6 cells. Unigene accession numbers for the genes not included in Figure 3 are dual specificity phosphatase 5 (DUSP5), Hs.2128; tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),: Hs.83429; death-associated protein kinase-related apoptosis-inducing protein kinase 2 (DRAK2), Hs.120996; human zinc finger protein 12 (HZF12), Hs.164284; regulator of G-protein signaling 16 (RGS16), Hs.183601; interferon regulatory factor 1 (IRF1), Hs.80645; EGF-response factor 2 (ERF-2), Hs.78909; early growth response 2 (EGR2), Hs.1395; serum-inducible kinase (SNK): Hs.3838; c-fos, Hs.25647; macrophage inflammatory protein 1-α (MIP1α), Hs.73817; THO2, Hs.16411; and TEB4, Hs.20141.